Ask AI
Back Back1

Closing the Gap Between Evidence and Practice: Adjuvant CDK4/6 Inhibitors in High-Risk HR-Positive/HER2-Negative Early Breast Cancer

Start Activity
Clinical Thought
Clinical Thought Start Activity
See Activity Information

Released: October 28, 2026

See Activity Collection

Step 1 of 2

1 ClinicalThought 2 Complete Activity

The treatment landscape for high-risk HR-positive/HER2-negative early breast cancer continues to evolve, with emerging evidence and adjuvant CDK4/6 inhibitors creating new opportunities to reduce recurrence risk and improve long-term outcomes. This expert commentary explores how healthcare professionals can translate findings from pivotal clinical trials into individualized, guideline-concordant treatment decisions while navigating differences in patient eligibility, efficacy, and safety profiles.

Jame Abraham
Jame Abraham, MD, FACP
Erin F. Cobain
Erin F. Cobain, MD
CDK46i in EBC

Continue

For patients with hormone receptor (HR)-positive, HER2-negative early breast cancer (EBC), completing surgery, radiation, chemotherapy when indicated, and endocrine therapy (ET) does not necessarily eliminate the risk of recurrence. This risk can persist for decades, particularly among patients with high-risk clinicopathologic features such as axillary lymph node involvement, large primary tumor size, grade 3 histology, or an elevated Ki-67 index. As our treatment options continue to evolve, we have an important opportunity to improve long-term outcomes through appropriate treatment intensification, individualized decision-making, and proactive supportive care. However, identifying the right patient for the right treatment is only the start of the process. Ensuring that patients can successfully remain on therapy is an equally important, long-term journey. 

Recognizing Persistent Recurrence Risk:

Erin Cobain, MD
Historically, ET has been the foundation of treatment for HR-positive/HER2-negative EBC. However, long-term follow-up studies demonstrate that recurrence risk extends well beyond the initial 5 years of treatment, increasing substantially with greater nodal involvement. These findings remind us that recurrence risk does not end after the first 5 years. We need to think about how we can better identify patients who remain at risk and offer treatments that can help prevent recurrence over the long term.

Emerging genomic evidence is also refining treatment selection. The phase III OPTIMA trial evaluated Prosigna-guided chemotherapy decisions in patients with HR-positive/HER2-negative EBC, including some with substantial nodal involvement. The results suggest that selected patients with lower genomic risk may safely avoid chemotherapy without compromising short-term invasive breast cancer–free survival.

Although these findings are encouraging, they also raise important questions about integrating genomic testing with newer adjuvant therapies. OPTIMA was conducted without adjuvant CDK4/6 inhibitors, so its findings should not be interpreted as establishing that these agents can replace chemotherapy. Rather, the study reinforces the importance of individualizing treatment according to both clinical and biologic risk.

One question I frequently encounter is how to manage node-negative patients with high genomic risk but limited clinical risk factors. I generally follow the eligibility criteria established in NATALEE. For patients with T1N0 disease, even with high genomic risk, I do not routinely recommend an adjuvant CDK4/6 inhibitor. However, for eligible patients with T2N0 disease and high genomic risk, I offer ribociclib based on the node-negative subgroup findings.

Applying the Evidence for Adjuvant CDK4/6 Inhibitors:

Jame Abraham, MD
The monarchE and NATALEE trials have meaningfully expanded our ability to reduce recurrence risk in patients with HR-positive/HER2-negative EBC. In monarchE, adding 2 years of abemaciclib to ET (tamoxifen or an aromatase inhibitor [AI]) improved invasive disease–free survival (iDFS) among patients with high-risk, node-positive disease. At approximately 7 years, iDFS was 77.4% with abemaciclib vs 70.9% with ET alone. Of importance, the trial also demonstrated a statistically significant overall survival (OS) benefit, with an absolute improvement of approximately 1.8%.

The NATALEE trial evaluated 3 years of ribociclib plus an AI in a broader population, including selected patients with high-risk, node-negative disease. At 5 years, the absolute iDFS improvement was approximately 4.5%, with a 5.7% difference observed in the node-negative subgroup. OS data remain immature, but a favorable trend continues to be observed with ribociclib plus an NSAI.

These findings are clinically meaningful, but abemaciclib and ribociclib should not be considered interchangeable. Their trial populations, treatment durations, ET backbones, safety profiles, and maturity of survival evidence differ. For patients eligible for both agents, we must consider recurrence risk, comorbidities, concomitant medications, prior treatment tolerance, and patient preferences. The side effect profile often guides this decision. For example, significant diarrhea with prior adjuvant therapy may make abemaciclib a less suitable choice, whereas a history of significant hepatotoxicity or cardiac concerns may weigh against ribociclib. Some patients prioritize a shorter treatment duration, whereas others may prefer a different tolerability profile, even if treatment lasts longer. This is where shared decision-making becomes essential.

Making Treatment Tolerability a Clinical Priority:

Erin Cobain, MD
One of the most important things we can do to help patients stay on treatment is to prepare them for potential side effects before the first dose.

Diarrhea is common with abemaciclib and can substantially affect quality of life. Patients should have antidiarrheal medication available and understand when to use it. If diarrhea persists despite supportive care, treatment interruption and dose reduction may be appropriate. We should encourage patients to report symptoms early rather than struggle through treatment.

Neutropenia is more common with ribociclib, particularly at higher grades. Complete blood counts should be monitored before treatment, every 2 weeks during the first 2 cycles, at the beginning of the next 4 cycles, and subsequently as clinically indicated.

Nurses play an integral role in reinforcing these monitoring requirements and helping patients understand when treatment may need to be held, reduced, or resumed. Having clear dose-modification algorithms readily available can support consistent management.

Both agents can cause hepatotoxicity, requiring baseline and ongoing liver function monitoring. Ribociclib also carries a risk of QT interval prolongation, making ECG monitoring, electrolyte assessment, and careful review of concomitant medications important.

Comorbidities can further guide treatment selection. For patients with baseline diarrhea or inflammatory bowel disease, I may favor ribociclib. Conversely, significant QT-related concerns or interacting medications may favor abemaciclib. These considerations help us tailor treatment to the individual patient.

Strengthening Communication and Multidisciplinary Care:

Jame Abraham, MD
Effective treatment requires coordinated support from the entire oncology team. Medical oncologists, nurses, pharmacists, navigators, and other healthcare professionals all have important roles in identifying eligible patients, monitoring toxicities, and addressing barriers to adherence.

We must remember that many patients beginning adjuvant CDK4/6 inhibitor therapy have already undergone months of intensive treatment. Asking them to commit to another 2 or 3 years can feel overwhelming. In my practice, I try to introduce the possibility of additional therapy early, but I do not necessarily have every conversation at the first postchemotherapy or postradiation visit. Giving patients time to recover and introducing treatment decisions gradually can make the process more manageable.

These conversations should help patients understand their risk of recurrence, the potential benefits of treatment, and possible side effects. We also need to explain the dosing schedule and why taking treatment as prescribed matters. Clear expectations help patients make informed decisions and prepare for the commitment ahead.

Trust and open communication are equally important. Patients should feel comfortable contacting the care team as soon as side effects arise so that we can provide timely guidance and supportive care. I also believe we need to listen carefully when patients describe adverse effects. With abemaciclib-associated diarrhea, for example, I am comfortable holding treatment, reassessing symptoms, and reducing the dose when needed. The first 2 months are particularly important for optimizing tolerability.

Ultimately, our goal is not simply to prescribe effective therapy but to help patients receive it successfully. Early communication, realistic expectations, and ongoing supportive care can improve treatment tolerance and help patients gain the greatest possible benefit from therapy.

Your Thoughts:
How has the availability of adjuvant CDK4/6 inhibitors changed your approach to treating high-risk HR-positive/HER2-negative EBC? What strategies have been most effective in helping your patients manage adverse events and remain on treatment?

Continue

Poll

1.

In your clinical practice, what is the greatest challenge to optimizing adjuvant CDK4/6 inhibitor therapy for patients with high-risk HR-positive/HER2-negative EBC?

Submit